ORIP SERCA K01 Recipient R03 Eligibility Guide
Updated 7 official sources
Quick Answer: PAR-25-176 expired on May 8, 2026, and no reissue was posted as of October 9, 2026.
Full answer and how we checked it
ORIP has reissued this limited competition 3 times since 2017, so eligibility for a new version will likely turn on the same 7 checks: ORIP SERCA K01 status, an active K01 (with month 24 as the encouraged timing), limited-competition fit, 2-year R03 scope, no clinical trial, independence pathway, and project size.
Who this is for: This guide is for ORIP SERCA K01 recipients, mentors, department chairs, and sponsored-research offices checking ORIP SERCA K01 R03 eligibility before building a small grant plan.
Data note: This guide uses NIH PAR-25-176 (opens in a new tab), ORIP program information (opens in a new tab), NIH R03 activity code information (opens in a new tab), NIH clinical trials policy (opens in a new tab), Grants.gov listing 357188 (opens in a new tab), Grants.gov records of earlier versions, and NIH RePORTER award records, rechecked October 9, 2026.
In this guide
- Source Check
- Budget, Timing, and Review Rules From PAR-25-176
- What Funded SERCA R03s Looked Like
- 7 ORIP SERCA K01 R03 Eligibility Checks
- 5 Source Facts Applicants Should Know
- What NIH Doesn't Tell You
- 6 Evidence Assets That Make This R03 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 14-Day ORIP SERCA R03 Readiness Plan
- 6 Final Research Checks Before Submission
- Sources
Quick Facts
- Agency
- HHS
- Last deadline
- May 7, 2026 (passed)
- Status
- Closed
Assistance Listing 93.351: all awards
Source: USASpending.gov FY2024These figures cover all National Institutes of Health awards under Assistance Listing 93.351, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.
- Total Awards (FY2024, whole listing)
- 851
- Avg Award (whole listing)
- $3,278,472
- Median Award (whole listing)
- $600,000
- Total Funding (FY2024, whole listing)
- $279.0M
- YoY Funding Trend
- -0.4%
Data last verified: May 19, 2026
According to NIH PAR-25-176 (opens in a new tab), this limited competition supports ORIP-supported Special Emphasis Research Career Award K01 recipients. The overview describes recipients who have completed the first 24 months, but the eligibility section only says they're "encouraged" to apply after that point; the hard rules are an active K01, not in a no-cost extension, and no R01 or equivalent. NIH marks the route R03 Clinical Trial Not Allowed.
The core question is simple but strict: are you the right K01 recipient at the right point in the award, with a project that fits a 2-year small grant? Applicants can waste time trying to turn a career transition problem into an R03 when the eligibility gate was never met.
Use this guide with the live ORIP SERCA K01 recipient R03 program record, NIH K99/R00 pathway to independence, NIH SHINE R01 guide, NIH S15 shared-use equipment guide, what is a NOFO, BRAIN BBQS sensor U01 guide, and the Grantsights grant database.
Source Check
Checked October 2026.
As of October 9, 2026, NIH marks PAR-25-176 as expired; its expiration date was May 8, 2026, and its last listed due date was May 7, 2026. It remains useful for SERCA K01 recipients and research administrators who need to understand the closed-cycle rule set, prepare for a possible reissue, or choose another NIH route.
The closed-cycle facts are still important: PAR-25-176 was limited to ORIP-supported SERCA K01 recipients, NIH said applicants were encouraged to submit after completing the first 24 months of the K01, the K01 had to be active and not in no-cost extension at submission, R03 scope had to fit a small 2-year project, and clinical trials were not allowed.
Grants.gov search records (opens in a new tab) show the same limited competition under PAR-17-301 (2017), PAR-21-090 (2020), PAR-23-127 (2023), and PAR-25-176 (2024), roughly every two years. No forecast for a fifth version was listed on October 9, 2026. If your K01 is still active, ask the ORIP contact named in the NOFO whether a reissue is planned before your award's 24-month point passes.
Budget, Timing, and Review Rules From PAR-25-176
The PAR-25-176 notice (opens in a new tab) set limits that a reissue would likely repeat:
| Rule | What the NOFO said |
|---|---|
| Direct costs | Limited to $75,000 per year |
| Project period | No more than 2 years |
| K01 status | Active, not in a no-cost extension, at submission |
| R01 holders | Not eligible if you've received an R01 or equivalent (as defined in NOT-OD-08-065) |
| Lifetime limit | Only one R03 per SERCA K01 awardee under this NOFO |
| Second year | Doesn't need concurrent K01 support |
| Resubmissions | Allowed any time before the K01 expires, if it's still active |
| Required extras | A summary of the K01 aims and progress, with no overlap in science or funding, and a letter from the K01 mentor |
Reviewers scored the usual NIH factors plus NOFO-specific questions: how the R03 will advance the awardee toward independence, whether the plan is feasible in 2 years, whether the application gives a timeline for submitting an R01 or other independent support, and whether the mentor letter addresses independence potential and the continuing mentor relationship. ORIP framed the program around veterinary scientists, who it says often depend on a senior investigator's funding and struggle to build preliminary data of their own.
What Funded SERCA R03s Looked Like
Grantsights checked each NOFO number against NIH RePORTER (opens in a new tab) records pulled October 13, 2026. Grantsights analysis of those records shows a small, steady program, with 8 new R03s under PAR-17-301, 4 under PAR-21-090, 1 under PAR-23-127, and 2 so far under PAR-25-176, both starting July 1, 2026. Every award requested exactly $75,000 in direct costs, with total annual awards between about $111,000 and $124,000.
| NOFO | Example award | Recipient | FY and total |
|---|---|---|---|
| PAR-25-176 | 1R03OD040606-01, GCPII-mediated glutamate signaling in the gut | Johns Hopkins University | FY2026, $116,625 |
| PAR-25-176 | 1R03OD039968-01, preclinical models of osimertinib-resistant brain metastasis | UC San Diego | FY2026, $120,000 |
| PAR-23-127 | 1R03OD036470-01, Ptpn2 in B cells in autoimmunity | University of Colorado Denver | FY2024, $117,000 |
| PAR-21-090 | 1R03OD031958-01A1, core binding factor beta | UC Davis | FY2023, $111,350 |
| PAR-17-301 | 1R03OD026601-01, canine peripheral neuropathy genomics | University of Wisconsin-Madison | FY2019, $114,750 |
Recipients cluster at veterinary schools and academic medical centers, including NC State, Colorado State, Missouri, Tufts, and Boston University. All 4 PAR-21-090 awards were funded on a resubmission (A1), so a first-round miss isn't the end if the K01 is still active.
7 ORIP SERCA K01 R03 Eligibility Checks
Within 7 days, run 7 stop checks. If the first 2 fail, don't draft.
| Stop check | Strong R03 signal | Red flag |
|---|---|---|
| SERCA status | Applicant is an ORIP-supported SERCA K01 recipient | Different K award or no K award |
| K01 timing | K01 active, not in a no-cost extension, ideally past month 24 | K01 expired or in a no-cost extension |
| Limited competition | Applicant fits the exact pool | General early-stage investigator |
| Project size | Small, self-contained 2-year project | R01-size aims |
| Trial boundary | No clinical trial proposed | Human intervention trial appears |
| Independence path | Project helps transition to independence | Side project with weak career logic |
| Outputs | Feasible pilot, methods, data, or technology output | Open-ended exploration |
According to NIH, the R03 mechanism is intended for projects that can be completed in 2 years and require limited funding levels. That sentence should shape the aims.
5 Source Facts Applicants Should Know
Within 7 days, put 5 source facts into the decision memo. According to NIH, PAR-25-176 is a reissue of PAR-23-127. It is tied to ORIP, part of the Division of Program Coordination, Planning, and Strategic Initiatives.
USAspending.gov (opens in a new tab) data shows that the ORIP-connected assistance listing (93.351) had about $279.0M in FY2024 obligations across 851 awards active that year. Those are family-level figures, not the R03 cap. They help show why applicants need exact mechanism fit rather than broad NIH optimism.
| Fact | Source-backed read |
|---|---|
| NOFO | PAR-25-176 |
| Agency | ORIP, NIH |
| Mechanism | R03 Small Grant Program |
| Clinical trial status | Clinical Trial Not Allowed |
| Current source status | Expired May 8, 2026; no reissue as of Oct 9, 2026 |
NIH says R03 projects can include pilot and feasibility studies, secondary analysis, small self-contained research projects, development of research methods, and development of new research technology.
What NIH Doesn't Tell You
Within 7 days, answer 4 practical questions. First, this is not a rescue route for anyone near independence. SERCA K01 status and an active K01 are the core eligibility gates; the 24-month point is NIH's encouraged timing, not a bar.
Second, the R03 should support a specific next step. An awardee using it to test a new animal-model measurement method can tell a cleaner story than one trying to launch 3 disconnected aims.
Third, "Clinical Trial Not Allowed" needs an early check. If the project includes assigning humans to an intervention to evaluate a health-related biomedical or behavioral outcome, the route may be wrong.
Fourth, the R03 should help independence without pretending to be an R01. Write one main output and 2 linked aims, not a mini-version of a full program.
According to NIH, the route is marked Clinical Trial Not Allowed, so the no-trial check must happen before aims are drafted. According to Grants.gov, listing 357188 is the federal listing tied to this limited competition. According to ORIP, the award context is tied to research infrastructure and career development, which means the R03 should support a credible independence step rather than a broad extension of mentor work.
The practical read: if a reissue appears, a SERCA recipient with an active K01 past month 24, a PI-owned method output, and a small non-trial project is the target applicant. A recipient whose K01 is in a no-cost extension, who needs a clinical trial, or has an R01-sized project should skip this route and choose a better route before the rare career-stage window is spent.
6 Evidence Assets That Make This R03 Stronger
Within 14 days, build 6 evidence assets. Asset 1 is the eligibility memo. Include the SERCA K01 award number, start date, month 24 status, and ORIP support evidence.
Asset 2 is the 2-year work plan. Show what happens by quarter. If it cannot fit 8 quarters, it probably doesn't fit R03.
Asset 3 is the no-clinical-trial memo. According to NIH clinical trials policy (opens in a new tab), clinical trial status depends on assignment, intervention, and health-related biomedical or behavioral outcome. Check this before writing.
Asset 4 is the independence memo. Explain how the R03 output supports a future R01, equipment resource, method, model, or data asset.
Asset 5 is the mentor-independence boundary. A clean role split between mentor resource access and PI-owned aims reads better than a project that still looks like the mentor's work, and reviewers were told to evaluate that relationship.
Asset 6 is the route memo. Compare the R03 against an R21, R01, administrative supplement, foundation grant, and institutional bridge funds.
5 Route Choices Before Drafting
Within 7 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-176 reissue | SERCA K01 recipient has a small 2-year non-trial project | Expired; watch for a new number |
| R21 | Exploratory work is broader and not limited to SERCA pool | Different review lens |
| R01 | Scope needs a full project period and larger aims | R03 is too small |
| Supplement | Work extends an active award | Parent award route may fit |
| Foundation bridge | Timing or eligibility does not fit NIH | Faster route may fit |
Warning: if you are not an ORIP SERCA K01 recipient with an active K01, don't try to write around the rule. If you're earlier than month 24, ask the ORIP contact whether applying now makes sense.
6 Bad-Fit Signals
Within 7 days, stop on 6 bad-fit signals. First, the applicant is not in the limited competition pool. Second, the K01 has expired or is in a no-cost extension. Third, the project is an R01 in disguise.
Fourth, the project proposes a clinical trial. Fifth, the mentor still owns the core idea. Sixth, the output does not support independence.
Bad-fit R03s often have too many aims and too little career strategy. Keep the project smaller and sharper.
14-Day ORIP SERCA R03 Readiness Plan
Days 1 through 2 should confirm ORIP SERCA K01 status and month 24. Days 3 through 4 should write the no-clinical-trial memo and project-size check.
Days 5 through 8 should draft the 2-year work plan, independence logic, and output table. Days 9 through 11 should check mentor roles, budget fit, and route alternatives. Days 12 through 14 should finalize submission timing and NIH application mechanics.
Don't start with aims. Start with eligibility proof.
6 Final Research Checks Before Submission
Within 14 days, finish 6 final checks. Check 1 is NIH PAR-25-176 (opens in a new tab). Check 2 is ORIP program information (opens in a new tab). Check 3 is NIH R03 activity code information (opens in a new tab). Check 4 is NIH clinical trials policy (opens in a new tab). Check 5 is the Grants.gov listing. Check 6 is month-24 proof.
You're ready when the applicant can state SERCA status, month 24, non-trial status, 2-year output, independence value, and route reason in 6 direct sentences.
Sources
Largest awards active in FY2024
One row per recipient, its largest award | 851 Assistance Listing records | Avg: $3.3M
Oregon Health & Science University
OR
University of Washington
WA
Use the visible recipient rows as free source context
This program has no reviewed paid report today.
No reviewed paid report is currently offered for this program. The visible source rows remain free.
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the R03 record
Check expired PAR-25-176 status, SERCA K01 gate, 24-month rule, and no-trial status.
Compare K paths
Use when the applicant needs career-stage routing rather than a closed SERCA R03 cycle.
Compare mechanisms
Check whether R03, R21, R01, supplement, or bridge funding is the better path.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-25-176 fund?
It funded small grant projects for ORIP-supported SERCA K01 recipients with an active K01 not in a no-cost extension. NIH encouraged, but didn't require, applying after the first 24 months of the K01. NIH marks PAR-25-176 as expired as of May 8, 2026, and no reissue was posted as of October 9, 2026.
Is PAR-25-176 open to all early-stage investigators?
No. It is a limited competition for ORIP SERCA K01 recipients.
Does PAR-25-176 allow clinical trials?
No. NIH marks it R03 Clinical Trial Not Allowed.
What can an R03 support?
NIH says R03 projects can include pilot studies, feasibility studies, secondary analysis, small self-contained projects, methods work, and new technology development.
Who should skip PAR-25-176?
Skip it when you aren't an ORIP SERCA K01 recipient, your K01 has expired or is in a no-cost extension, you already hold an R01 or equivalent, the project needs more than 2 years, or a clinical trial is proposed.
Last updated October 13, 2026. Corrected October 13, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
NCMRR Early Career R03 Eligibility Guide
NCMRR Early Career R03 eligibility guide for PAR-25-124, 2-year R03 scope, $100,000 direct costs, trial fit, and R01 path.
NIH K01 Grant 2026: Eligibility, Salary, Page Limits
NIH K01 grant: 3 to 5 years at 75% effort, $75,000 to $100,000 salary at most institutes, NIAID rules, the 12-page limit and the Feb 12, 2027 due date.
NIH K01 Winners and Award History 2026
NIH K01 winners and award history from RePORTER FY2025 and FY2024 records, with recipient patterns, award amounts, IC mix, and career-stage fit.